Articles by Robert Cameron, MD, PhD
Face-Off: Award Presentation Ceremony
ByJoshua K. Sabari, MD,Roy S. Herbst, MD, PhD,Edward S. Kim, MD, MBA,Jyoti D. Patel, MD,Divya M. Gupta, MD,Laila A. Gharzai, MD,Rajat Thawani, MBBS,Faith Abodunrin, MD,Robert Cameron, MD, PhD Following a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.
Treatment Options for Patients with EGFRm NSCLC
ByJoshua K. Sabari, MD,Roy S. Herbst, MD, PhD,Edward S. Kim, MD, MBA,Jyoti D. Patel, MD,Divya M. Gupta, MD,Laila A. Gharzai, MD,Rajat Thawani, MBBS,Faith Abodunrin, MD,Robert Cameron, MD, PhD Experts on non–small cell lung cancer reflect on clinical trial data to weigh treatment options for patients with EGFR-mutated non–small cell lung cancer.
Will Neo-Adjuvant Therapies Replace Surgery plus Adjuvant Treatment for Resectable NSCLC?
ByJoshua K. Sabari, MD,Roy S. Herbst, MD, PhD,Edward S. Kim, MD, MBA,Jyoti D. Patel, MD,Divya M. Gupta, MD,Laila A. Gharzai, MD,Rajat Thawani, MBBS,Faith Abodunrin, MD,Robert Cameron, MD, PhD Jyoti D. Patel, MD, and Rajat Thawani, MBBS, tackle the question of whether neoadjuvant therapies will replace surgery plus adjuvant treatment for patients with resectable non–small cell lung cancer.
Patient Case: KRAS G12C Non–Small Cell Lung Cancer
ByJoshua K. Sabari, MD,Roy S. Herbst, MD, PhD,Edward S. Kim, MD, MBA,Jyoti D. Patel, MD,Divya M. Gupta, MD,Laila A. Gharzai, MD,Rajat Thawani, MBBS,Faith Abodunrin, MD,Robert Cameron, MD, PhD Robert B. Cameron, MD, PhD, offers insights on a patient with KRAS G12C non–small cell lung cancer.
Clinical Scenario: A PD-L1-Low Patient with NSCLC
ByJoshua K. Sabari, MD,Roy S. Herbst, MD, PhD,Edward S. Kim, MD, MBA,Jyoti D. Patel, MD,Divya M. Gupta, MD,Laila A. Gharzai, MD,Rajat Thawani, MBBS,Faith Abodunrin, MD,Robert Cameron, MD, PhD Focusing on PD-L1-low NSCLC, Faith Abodunrin, MD, discusses the decision to rechallenge with immunotherapy.
Patient Profile: A 57-Year-Old Woman with NSCLC
ByJoshua K. Sabari, MD,Roy S. Herbst, MD, PhD,Edward S. Kim, MD, MBA,Jyoti D. Patel, MD,Divya M. Gupta, MD,Laila A. Gharzai, MD,Rajat Thawani, MBBS,Faith Abodunrin, MD,Robert Cameron, MD, PhD Jyoti Patel, MD, presents the case of a patient with EGFR-mutated non–small cell lung cancer requiring treatment following osimertinib.
Patient Case: A 76-Year-Old Woman with ROS1+ Metastatic NSCLC
ByJoshua K. Sabari, MD,Roy S. Herbst, MD, PhD,Edward S. Kim, MD, MBA,Jyoti D. Patel, MD,Divya M. Gupta, MD,Laila A. Gharzai, MD,Rajat Thawani, MBBS,Faith Abodunrin, MD,Robert Cameron, MD, PhD Initiating a conversation on patient cases, Divya Gupta, MD, presents the profile of a 76-year-old woman with ROS1+ metastatic non–small cell lung cancer.
Amivantamab plus Lazertinib in Atypical EGFR-mutated Advanced NSCLC: Results from CHRYSALIS-2
ByJoshua K. Sabari, MD,Roy S. Herbst, MD, PhD,Edward S. Kim, MD, MBA,Jyoti D. Patel, MD,Divya M. Gupta, MD,Laila A. Gharzai, MD,Rajat Thawani, MBBS,Faith Abodunrin, MD,Robert Cameron, MD, PhD Divya Gupta, MD, presents data from CHRYSALIS-2 focused on amivantamab plus lazertinib in atypical EGFR-mutated advanced non–small cell lung cancer.
Osimertinib for EGFRm Stage III Unresectable NSCLC: The LAURA Trial
ByJoshua K. Sabari, MD,Roy S. Herbst, MD, PhD,Edward S. Kim, MD, MBA,Jyoti D. Patel, MD,Divya M. Gupta, MD,Laila A. Gharzai, MD,Rajat Thawani, MBBS,Faith Abodunrin, MD,Robert Cameron, MD, PhD Robert B. Cameron, MD, PhD, reviews data from the LAURA trial investigating osimertinib in patients with EGFR-mutated stage III unresectable NSCLC.
Lorlatinib vs Crizotinib in Patients With Advanced ALK-Positive NSCLC: 5-Year Outcomes from the Phase III CROWN Study
ByJoshua K. Sabari, MD,Roy S. Herbst, MD, PhD,Edward S. Kim, MD, MBA,Jyoti D. Patel, MD,Divya M. Gupta, MD,Laila A. Gharzai, MD,Rajat Thawani, MBBS,Faith Abodunrin, MD,Robert Cameron, MD, PhD Focusing on the CROWN study, Faith Abodunrin, MD, discusses the role of lorlatinib in the treatment of patients with non–small cell lung cancer.
BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in TKI-naïve ALK-rearranged Metastatic NSCLC
ByJoshua K. Sabari, MD,Roy S. Herbst, MD, PhD,Edward S. Kim, MD, MBA,Jyoti D. Patel, MD,Divya M. Gupta, MD,Laila A. Gharzai, MD,Rajat Thawani, MBBS,Faith Abodunrin, MD,Robert Cameron, MD, PhD Laila Gharzai, MD, discusses findings from the BRIGHTSTAR trial which evaluated brigatinib in TKI-naïve patients with ALK-rearranged metastatic non–small cell lung cancer.
Introduction of the Non–Small Cell Lung Cancer Face-Off
ByJoshua K. Sabari, MD,Roy S. Herbst, MD, PhD,Edward S. Kim, MD, MBA,Jyoti D. Patel, MD,Divya M. Gupta, MD,Laila A. Gharzai, MD,Rajat Thawani, MBBS,Faith Abodunrin, MD,Robert Cameron, MD, PhD Joshua K. Sabari, MD, introduces a Face-Off program in which Northwestern University and the University of Chicago will present data and discuss treatment practices in non–small cell lung cancer.
